171 results
Page 3 of 9
8-K
EX-10.1
btl8lx
5 Jan 22
Financial Statements and Exhibits
4:58pm
424B5
u6zet zvkk002069gkp
5 Jan 22
Prospectus supplement for primary offering
4:51pm
8-K
EX-99.1
u85w0485ly2pkl8emx7j
4 Jan 22
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
424B5
r0r1raqk
3 Jan 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
96n1l u6qbgdja
20 Dec 21
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
7:04am
8-K
EX-99.1
z37qyw udgep9yp4t
9 Nov 21
Intra-cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
dxl4ej6qxrdr2a2
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
vbd7 nienzco
10 May 21
Intra-cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
0gx58nh385
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
DEFA14A
b7608
20 Apr 21
Additional proxy soliciting materials
7:07am
PRE 14A
ucm6w1x44mcn2q20
19 Apr 21
Preliminary proxy
5:28pm
8-K
EX-99.1
wsla6d xlbs
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
EX-99.1
pv8avcl5akw aodpc9a
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am